CFO’s “Buy‑Now, Sell‑Later” Play at Capricor: Insider Confidence Amid Volatile Stock and FDA Countdown
Capricor CFO’s buy‑sell combo shows insider confidence in Deramiocel’s FDA review – a balanced risk‑reward play for investors.
3 minutes to read
CAPRICOR THERAPEUTICS INC
Capricor’s Insider Buying Surge Signals Confidence Ahead of FDA Decision on Deramiocel
Insider buying in Capricor shows strategic confidence: Litvack Frank’s low‑price share purchase signals long‑term commitment amid strong clinical results and a $279 M cash runway.
3 minutes to read
Capricor Therapeutics Director Executes Rule 144 Sale of 7,529 Shares at $32.11 — A Routine Liquidity Move Amid Biotech Rally
Capricor Therapeutics insider sale: Director Sabar Karimah Es sells 7,529 shares at $32.11 per share, a Rule 144 transaction that’s market‑neutral and part of a disciplined equity‑compensation plan – a routine liquidity move amid bullish biotech mom…
4 minutes to read
Capricor Insider Sabar Karimah Es Buys Shares at 15% of Market Price, Sells Under 10b‑5 Plan in Rapid Turn‑around Play
Capricor insiders, led by Sabar Karimah Es, buy low at $4.86 and sell near $30–$31, showing confidence in future upside amid a negative P/E and a Duchenne pipeline.
4 minutes to read
Capricor Executives Exercise Zero‑Cost Stock Options in Coordinated Move, Signaling Strong Confidence in Upcoming Milestones
Capricor insiders exercise 50,000 zero‑cost options—signaling confidence in its DMD pipeline and potential share price rally.
3 minutes to read
Capricor Executives Snap Up Zero‑Cost Options Amid DMD Milestone Hype, Stock Slides Slightly.
Capricor’s insider option buys signal confidence in its Duchenne therapy pipeline, but investors should weigh clinical risks and market volatility.
3 minutes to read